Both STAC2 and NELL1 promoter CpG island hypermethylation has been reported in metastatic breast cancer and primary colon cancer, respectively and GRP is implicated in the development of tumorigenicity and drug resistance. This evidence concerns the gene NELL1 and colonic neoplasm.